This phase II trial tests the safety and best dose of revumenib in combination with chemotherapy, and evaluates whether this treatment improves the outcome in infants and young children who have leukemia that has come back (relapsed) or does not鈥�
- Investigators
- Brian Stover, William Slayton
- Status
- Accepting Candidates
- Ages
- 1 Month - 6 Years
- Sexes
- All